Cutaneous Reactions to Transdermal Therapeutic Systems

Andrea L. Musel; Erin M. Warshaw

Disclosures

Dermatitis. 2006;17(3):109-122. 

In This Article

Management of Cutaneous Reactions to TTS

Management of cutaneous reactions includes rotation of application sites, TTS placement on the buttocks, trials of alternate brands, a shorter duration of occlusion, and pretreatment of the skin with topical corticosteroids.[1,24,70,71,72,73,74] Davis and Winter evaluated 3,816 TTS sites on 53 women who were using Estraderm 0.05 placebo TTSs and who were tested against a control adhesive TTS. The authors found that irritant reactions were minimized (92% decrease in cumulative irritation score) by rotation of application sites and placement on the buttocks rather than the abdomen or lower back.[71] Kounis and colleagues reported that 10 of 21 (48%) patients who experienced cutaneous reactions to one brand of nitroglycerin TTS were able to successfully transition to another brand, with no cutaneous side effects, indicating that a change of brand in some cases might help avoid future reactions.[24] For 3 months, Weber and Drayer observed 101 patients using clonidine TTS and suggested that cutaneous reactions might be improved by decreasing the occlusion time from 7 days to 3 to 5 days.[70]

Pretreatment and coadministration of topical steroids with TTSs have been advocated as methods to improve irritation and allergic contact dermatitis at TTS application sites.[72,75,76] Pretreatment of TTS sites with topical corticosteroids was evaluated in an open-label controlled pilot study of 65 men who each served as his own control. Pretreatment of testosterone TTS placement sites with triamcinolone acetonide 0.1% cream was found to lower the incidence and severity of skin irritation.[77] Pretreatment of application sites with an aerosol spray containing beclomethasone dipropionate has also been shown to decrease skin reactions among users of clonidine TTSs.[1] In one report, pretreatment of testosterone TTS application sites with clobetasone butyrate 0.05% cream 30 minutes prior to placement was found to prevent dermatitis, without impairment of drug delivery.[33] This regimen enhanced compliance and may work for other patients who have allergic contact dermatitis and who are not candidates for other modes of drug delivery.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....